An Extension Study to Evaluate Casimersen or Golodirsen in Patients With Duchenne Muscular Dystrophy
Trial ID or NCT#
NCT03532542
Status
Purpose
The main objective of this study is to evaluate the safety and tolerability of long-term treatment with casimersen or golodirsen in patients with Duchenne muscular dystrophy (DMD).
Official Title
Long-term, Open-label Extension Study for Patients With Duchenne Muscular Dystrophy Enrolled in Clinical Trials Evaluating Casimersen or Golodirsen
Eligibility Criteria
Ages Eligible for Study: 7 Years to 23 Years
Sexes Eligible for Study: MALE
Accepts Healthy Volunteers: No
Investigator(s)
John W. Day, MD, PhD
Neuromuscular neurologist,
Neurophysiologist
Professor of Neurology and Neurological Sciences (Adult Neurology), of Pediatrics (Genetics) and, by courtesy, of Pathology
View on ClinicalTrials.gov